RDHL · RedHill Biopharma Ltd.

This Nasdaq non-compliance notice represents a HIGH material event because sustained failure to meet the $1.00 minimum bid price requirement threatens the Company’s continued listing on a U.S. national exchange — a critical factor for institutional eligibility, index inclusion, and investor access. The deficiency stems from persistent market valuation pressure over a defined 30-business-day window, not a one-time anomaly, suggesting underlying concerns about investor confidence, clinical or commercial progress, or capital structure sustainability. While RedHill retains full trading privileges during the 180-day cure period and reports no operational impact, the absence of disclosed remediation actions — such as a reverse stock split proposal, strategic update, or financing announcement — leaves investors without visibility into management’s concrete plan to restore compliance. Nasdaq’s process does not guarantee additional time beyond October 5, 2026, and delisting would trigger mandatory deregistration, reduced liquidity, increased volatility, and potential forced selling by funds with exchange-only mandates. The fact that the notice was issued under Rule 5550(a)(2), rather than a more flexible rule like 5810(c)(3)(A) for other deficiencies, confirms the narrow, price-specific nature of the risk — making share price performance over the next six months a decisive indicator of corporate stability.